Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

被引：36

作者：

Camus, Baptiste ^{[1
,2
]}

Cottereau, Anne-Segolene ^{[2
,3
]}

Palmieri, Lola-Jade ^{[1
,2
]}

Dermine, Solene ^{[1
,2
]}

Tenenbaum, Florence ^{[3
]}

Brezault, Catherine ^{[1
,2
]}

Coriat, Romain ^{[1
,2
]}

机构：

[1] Cochin Hosp, AP HP Ctr, Gastroenterol & Digest Oncol Unit, 27 Rue Faubourg St Jacques, F-75014 Paris, France

[2] Univ Paris, Fac Med, F-75006 Paris, France

[3] Cochin Hosp, AP HP Ctr, Dept Nucl Med, 27 Rue Faubourg St Jacques, F-75014 Paris, France

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期

关键词：

neuroendocrine tumors; neoplasm metastasis; PRRT; peptide receptor radionuclide therapy; gastroenteropancreatic tumor; pulmonary tumor; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; LU-177-DOTATATE; EFFICACY; LU-177-OCTREOTATE; FEASIBILITY; TOXICITY; SURVIVAL; NEN; G3;

D O I：

10.3390/jcm10061267

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are Y-90-DOTATOC and Lu-177-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared(177)Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.

引用

页码：1 / 18

页数：15

共 50 条

[1] Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
van Vliet, Esther I.
Teunissen, Jaap J. M.
Kam, Boen L. R.
de Jong, Marion
Krenning, Eric P.
Kwekkeboom, Dik J.
NEUROENDOCRINOLOGY, 2013, 97 (01) : 74 - 85
[2] Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Kwekkeboom, Dik J.
de Herder, Wouter W.
van Eijck, Casper H. J.
Kam, Boen L.
van Essen, Martijn
Teunissen, Jaap J. M.
Krenning, Eric P.
SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 78 - 88
[3] Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Bertani, E.
Chiappa, A.
Fazio, N.
Grana, C.
Bodei, L.
Falconi, M.
Ravizza, D.
Spada, F.
Andreoni, B.
NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 285 - 285
[4] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
Bodei, L.
Pepe, G.
Paganelli, G.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
[5] The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
Hindie, Elif
Baudin, Eric
Hicks, Rodney J.
Taieb, David
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) : 522 - 524
[6] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
Otte, Andreas
HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (02): : 182 - 182
[7] Efficacy of the Chronic Lanreotide Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP/NET) after Peptide Receptor Radionuclide Therapy (PRRT)
Szalus, N.
Kaminski, G.
Podgajny, Z.
Dziuk, E.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 137 - 137
[8] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
Papamichail, Dimitris G.
Exadaktylou, Paraskevi E.
Chatzipavlidou, Vasiliki D.
HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (01): : 75 - 83
[9] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
Duan, H.
Ferri, V.
Kunz, P. L.
Fisher, G. A.
Moradi, F.
Davidzon, G. A.
Franc, B. L.
Iagaru, A. H.
Mari, C. Aparici
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
[10] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Duan, H.
Girod, B.
Ninatti, G.
Ferri, V
Kunz, P.
Fisher, G.
Moradi, F.
Davidzon, G.
Franc, B.
Lagaru, A.
Aparici, Mari C.
NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252

← 1 2 3 4 5 →